Send to

Choose Destination
Europace. 2013 Oct;15(10):1526-32. doi: 10.1093/europace/eut292.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey.

Author information

University of Birmingham Centre for Cardiovascular Sciences, City Hospital Birmingham, Birmingham B18 7DH, UK.


The purpose of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke prevention in atrial fibrillation (AF), particularly into the use of novel oral anticoagulants (NOACs) for stroke prevention, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of NOACs for stroke prevention in AF. There were clear practice differences evident, and also the need for greater adherence to the guidelines, especially since guideline adherent management results in better outcomes in AF.


Anticoagulation; Apixaban; Atrial fibrillation; Dabigatran; EHRA survey; EP wire; Guidelines; New oral anticoagulants; Rivaroxaban; Stroke; Warfarin

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center